Q: Do you think there is too much “hype” about avian influenza and a possible human pandemic? What happens if there is no pandemic in the next six months? Will that not detract from the credibility of WHO and the United Nations?

A: As a global public health agency, WHO has a responsibility to alert the international community when it appears that the world is moving closer to a pandemic. It may be years before a pandemic hits the world, and it may ultimately be sparked by a virus other than [avian influenza virus] H5N1. Investing in pandemic preparedness is essentially like investing in an insurance policy, and while we hope that we never have to make a claim, we also know that whatever investment we make now in strengthening global public health infrastructures will have benefits for our responses to all future infectious disease threats. The preparations that we make for a pandemic are not disease specific; they will increase our capacity to respond to all future outbreaks, including SARS (severe acute respiratory syndrome) and other new and emerging diseases.

Q: Some members of the public in some countries believe vaccines for a human pandemic influenza will be available as soon as a pandemic is announced. How can governments dispel the public’s unrealistic expectations about vaccine availability?

A: WHO advises governments to address such issues openly and rapidly. Because the pandemic strain has not yet emerged, there is no such vaccine currently available. Since a pandemic vaccine needs to be a close match to the pandemic virus, commercial production cannot begin prior to the emergence and characterization of the pandemic virus. It is likely that vaccine production, in any significant amounts, will take at least six months. It is therefore highly unlikely that there will be any large quantities of pandemic vaccine available during the first wave of a pandemic.

Q: SARS was a lesson in openness and transparency. If you are not open right away, it haunts you. Do you think governments have learned from the experience of SARS, that if they are not open and transparent from the start they may be heading for disaster?

A: Yes, SARS was an excellent example in demonstrating to countries that because infectious diseases do not respect borders, there is no such thing as a localized outbreak. An outbreak in one country one day can very rapidly become a problem for countries on the other side of the world. WHO hopes that countries realize that while they may be reluctant to report disease outbreaks, if they do so quickly and transparently, WHO can provide them with technical guidance and support, if it is needed, to contain such outbreaks.

Q: How is WHO advising governments on the use of masks in the event of a human influenza pandemic or other infectious diseases?

A: Because the pandemic virus has not yet emerged, there is no such specific guidance at the moment. While WHO has existing recommendations for issues, such as personal hygiene and mask usage primarily for healthcare workers, such guidance is based on general transmission patterns of seasonal human influenza. It is not known how effective this guidance would be in slowing the spread of a pandemic. Thus, any recommendations that WHO provides in the pre-pandemic period, and even once the pandemic starts, may be modified once more information about the pandemic strain is obtained, such as its infection rate and its lethality.

Q: How do you bring members of the medical profession on board so that those who don’t believe what public health people are saying do not contradict public health messages?

A: WHO recognizes the need to work closely with medical professionals, since they are a very valuable ally in containing outbreaks and implementing control measures.

WHO clinical trials initiative to protect the public

In response to calls for new standards and rules for the registration of studies involving humans participants, WHO is developing a common set of rules for registering clinical trials.

WHO plans to launch a global network of clinical trial registers in May 2006, the first step towards establishing a web-based search platform where members of the public can obtain full and detailed information about clinical trials. Currently, there are at least 50 registers of clinical trials around the world. The WHO International Clinical Trials Registry Platform is a major initiative to bring these registers together in a global network to provide a single point of access to the information stored in them.

The goal is to increase transparency and accountability on the part of companies and institutions that do clinical research, and, in turn, boost public trust and confidence in that research. “Registration of trials promotes scientific and ethical integrity and makes research more honest. When the system is up and running there will be no hiding of results,” said Dr Patrick Unterlerchner, WHO Health Systems Analyst and Assistant to the Coordinator of the project.

The initiative comes in the wake of several cases of companies withholding negative research findings that sparked public outrage. Merck of the United States withdrew Vioxx from the market in 2004 after the drug was linked to an increased risk of heart attack and stroke, and in 2003, GlaxoSmithKline of the United Kingdom warned that the antidepressant, Paxil, should not be prescribed to minors as it could increase the risk of suicide.

In response, the International Committee of Medical Journal Editors (ICMJE), representing the world’s leading medical journals, agreed not to publish the results of any clinical trial unless that trial had been registered in a public register before the enrolment of the first patient.
WHO News

Recent news from WHO

- WHO Director-General LEE Jong-wook visited parts of Pakistan that were affected by the 8 October 2005 earthquake. He praised the response of the government and the international community to the disaster, but said that WHO still needs US$ 13 million, almost half of the US$ 27 million initially requested to help people there survive the winter. Hundreds of thousands of people still need better shelter, the cold and the crowded conditions in some camps increase the risk of respiratory infections, and getting health care to people who live high in the mountains is a major challenge.


- Every year millions of people are pushed into poverty because of high medical costs paid for out of their own pockets. Experts from 40 countries at a conference in Berlin looked at ways to provide social protection for people who cannot afford these costs and to promote investment in health. The 5–7 December meeting was convened by the Deutsche Gesellschaft für Technische Zusammenarbeit GmbH, the German Federal Ministry for Economic Cooperation and Development, the International Labour Organization and WHO.

- WHO and the UN Food and Agriculture Organization made it clear on 5 December that it is safe to eat chicken, eggs and other poultry products as long as they are properly cooked. They issued this advice to national food safety authorities after sales of poultry products fell over consumer fears that these products might be infected with a bird flu virus.

- Lesotho launched a groundbreaking campaign on World AIDS Day, 1 December, to encourage everyone in the southern African country to get tested for HIV. Lesotho is offering confidential and voluntary HIV testing and counselling door-to-door with the goal of reaching all households in Lesotho by the end of 2007.

- With an additional US $1 billion per year, immunization could save 10 million more lives in a decade. With this increased investment, more than 70 million children in the world’s poorest countries would be protected each year against 14 major childhood diseases by 2015, according to a WHO/UNICEF study presented at the 7–9 December meeting of representatives of the Global Alliance for Vaccines and Immunization (GAVI).

For more about these and other WHO news items please see: http://www.who.int/mediacentre/events/2005/en/index.html